Ownership and insider activity for Kiniksa Pharmaceuticals International, plc (KNSA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Price
| Price | $76.27 |
| Market Cap | $5.8B |
| Exchange | NASDAQ |
| Country | GB |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Ragosa Mark | A-Award | 31,150 | $2.5M |
| 2026-09-01 | Ragosa Mark | M-Exempt | 3,069 | |
| 2026-09-01 | Ragosa Mark | M-Exempt | 1,591 | |
| 2026-09-01 | Ragosa Mark | F-InKind | 4,404 | $349K |
| 2026-09-01 | Ragosa Mark | M-Exempt | 1,750 | |
| 2026-09-01 | Ragosa Mark | M-Exempt | 2,694 | |
| 2026-09-01 | Ragosa Mark | M-Exempt | 3,069 | |
| 2026-09-01 | Ragosa Mark | A-Award | 7,800 | |
| 2026-09-01 | Ragosa Mark | M-Exempt | 1,591 | |
| 2026-09-01 | Ragosa Mark | M-Exempt | 1,750 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $56.0M | $45.6M | $307.3M | $46.9M | $114.0M | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M |
| Short-term Investments | 0 | 0 | 0 | $186.5M | $209.4M | $59.7M | $67.9M | $98.4M | $60.0M | $248.5M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $4.0M | $20.3M | $21.3M | $41.7M | $15.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $3.7M | $21.6M | $31.1M | $26.4M | $54.9M |
| Total Current Assets | $56.3M | $47.1M | $313.8M | $241.6M | $333.2M | $196.4M | $243.1M | $276.3M | $331.8M | $527.2M |
| Property, Plant & Equipment | $84000 | $125000 | $6.4M | $8.3M | $10.6M | $8.4M | $7.0M | $12.7M | $11.0M | $11.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $19.2M | $18.2M | $17.2M | $16.2M | $15.2M |
| Total Assets | $56.5M | $47.5M | $322.0M | $254.5M | $349.5M | $232.8M | $459.7M | $526.3M | $580.6M | $763.6M |
| Accounts Payable | $212000 | $1.2M | $10.9M | $5.7M | $503000 | $1.9M | $7.9M | $8.2M | $2.0M | $2.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.0M |
| Total Current Liabilities | $2.3M | $17.4M | $42.6M | $27.8M | $31.8M | $44.8M | $47.1M | $63.7M | $100.6M | $139.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $82.2M | $137.2M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142.1M | $196.0M |
| Retained Earnings | -$26.1M | -$91.0M | -$194.2M | -$356.1M | -$517.5M | -$675.4M | -$492.0M | -$477.9M | -$521.1M | -$462.1M |
| Total Equity | -$25.7M | -$89.7M | -$194.2M | $225.4M | $311.9M | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M |
| Total Debt | 0 | 0 | 0 | $2.7M | $7.0M | $6.0M | $5.9M | $12.3M | $9.9M | $9.5M |
| Net Debt | -$56.0M | -$45.6M | -$307.3M | -$230.7M | -$316.5M | -$176.2M | -$184.7M | -$194.1M | -$233.8M | -$404.6M |
| Working Capital | $54.0M | $29.7M | $271.2M | $213.8M | $301.4M | $151.6M | $196.0M | $212.6M | $231.2M | $388.0M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.90 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 10.35 |
Profitability
| Return on Equity | 13.65% |
| Return on Invested Capital | 9.71% |
| Return on Assets | 9.00% |
| Gross Margin | 54.49% |
| Operating Margin | 11.92% |
| Net Margin | 9.59% |
Related companies: ADPT · APLS · CDTX · CPRX · FOLD · IDYA · MLYS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of KNSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks